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recent years (5, 6) . However, the current definition for vitamin D status and related recommendations are mainly based on evidence from white populations, whereas vitamin D metabolism and related health conditions may vary across different racial groups (6) (7) (8) (9) . For instance, low 25(OH)D was associated with a high risk of coronary heart disease or reduced bone mineral density in whites, but not in blacks (7, 10) . Moreover, to achieve a target 25(OH)D of 50 nmol/L, the estimated daily recommended dietary allowance for vitamin D was 800 IU for whites (11) , 1640 IU for blacks (12) , and .2000 IU [the tolerable upper intake level (UL) in China] for Chinese in our previous trial (13) . Thus, it is critically important to clarify whether the commonly used definition for vitamin D status and related recommendation are appropriate for nonwhite populations.
Vitamin D-binding protein (VDBP), encoded by the GC gene, binds to 85% to 90% circulating 25(OH)D and thereby regulates the vitamin D bioavailability (14) . Bioavailable 25(OH)D [25(OH)D Bio ], the non-VDBPbound portion, including albumin bound and free form, appears to be more biologically active in targeted tissues than in VDBP-bound 25(OH)D, according to the free hormone hypothesis (15, 16) , which has been proposed as a universal mechanism for cellular uptake of steroid hormones and also applied to measurement of free forms of testosterone, cortisol, and thyroxine in clinical settings (17) . With different combinations of common polymorphisms in GC, there were 3 major VDBP isoforms (Gc1F, Gc1S, and Gc2), and their concentrations varied according to measurement methods (18) . For instance, VDBP levels were significantly lower in blacks than in whites when using the monoclonal antibody immunoassay, whereas no racial differences were detected when using polyclonal antibody immunoassay or proteomics (18) (19) (20) (21) . It was plausible that the monoclonal antibody immunoassay bound preferably to Gc1S and Gc2 rather than to Gc1F, a more highly prevalent isoform in blacks (92.7%) than in whites (6.0%) (18, 22) . Compared with blacks and whites, Asians have a different VDBP isoform distribution (23) , and it remains unknown how monoclonal and polyclonal antibody immunoassays influence VDBP levels.
Previous studies in Europeans and Chinese suggested that genetic variants in GC, CYP2R1 (25-hydroxylase), and 7-dehydrocholesterol reductase (DHCR7) were associated with 25(OH)D concentrations (24) (25) (26) . Clinical trials also indicated that nongenetic factors, including body mass index (BMI), baseline concentration, supplemental form, dose, and duration could influence 25(OH)D responses (11) (12) (13) 27 
Subjects and Methods

Study design and participants
This randomized, placebo-controlled trial was conducted between January and May of 2014 for 20 weeks in Shanghai, China. After being recruited by an advertisement, a total of 1815 volunteers in Shanghai were screened by questionnaires and physical examination (Supplemental Fig. 1 To ensure the double blinding, the placebo and vitamin D 3 capsules had similar appearance and smell (provided by Sinopharm Xingsha Pharmaceuticals, Xiamen, China). An independent laboratory (Royal DSM China Campus, Shanghai, China) evaluated the vitamin D 3 contents of capsules 3 times. The average doses were 0 for placebo and 1940 IU for 2000 IU vitamin D 3 capsules. All participants were required to (1) maintain their habitual food intake and physical activity, (2) minimize sun exposure and vitamin D-rich foods such as fatty fish and cod liver oil as much as possible, and (3) avoid taking nontrial vitamin D supplements. The participants were asked to return all untaken capsules weekly, and adherence was assessed by capsule counts ([(supplied number 2 returned number)/supplied number] 3 100%).
Data collection
A face-to-face interview was conducted by trained dieticians at weeks 0, 10, and 20 (13) . The information on demographics, health status, lifestyles (physical activity, sun exposure, and dietary intake), family history of diseases, medical history, medication log, and intake of nutritional supplements was collected by using standardized questionnaires (13) . Total physical activity levels were categorized as low, moderate, or high based on standardized protocols (28) . Dietary intake was obtained by 3-day food records (2 weekdays plus 1 weekend day). Sun exposure levels were estimated by self-reported weekly outdoor hours from 10:00 AM to 3:00 PM (13) . Sun exposure protection score was calculated according to the frequency of wearing hats, long sleeves, and using sunscreen within the previous month (13) . Body weight, height, and blood pressure were measured by standardized procedures (13) , and BMI was calculated as weight (kg)/height (m) 2 .
Biochemical analyses
Overnight fasting blood samples were obtained at weeks 0, 10, and 20. Serum 25(OH)D was measured by liquid chromatography-tandem mass spectrometry with deuterated internal standards (Sigma-Aldrich, St. Louis, MO), and the interassay and intraassay coefficients of variation (CVs) were #8.3%. VDBP was measured by (1) a monoclonal antibody ELISA kit (R&D Systems, Minneapolis, MN) with the interassay and intraassay CVs # 7.2%; and (2) a polyclonal antibody ELISA kit (Immunodiagnostik, Bensheim, Germany) with the interassay and intraassay CVs # 8.1%. Serum parathyroid hormone (PTH) was measured by an ADVIA Centaur XP immunoassay system (Siemens Healthcare, Erlangen, Germany) with the interassay and intraassay CVs # 7.4%. Serum calcium, albumin, alanine transaminase, aspartate aminotransferase, g-glutamyl transferase, creatinine, urea nitrogen, and uric acid concentrations were measured by an automatic biochemical analyzer (Hitachi 7080) using reagents purchased from Roche Diagnostics (Mannheim, Germany), and all interassay and intraassay CVs were #8.6%.
Genotyping
Based on the findings from our studies and those of others (25, 26, 29) , GC-rs7041, GC-rs4588, vitamin D receptor (VDR)-rs2228570, CYP2R1-rs10741657, DHCR7-rs1790349, and CYP24A1-rs6013897 were selected and an effect allele was defined as 25(OH)D-raising allele, accordingly. The reproducibility of genotyping was 100% among 10% duplicated samples. Effect allele frequencies in our participants were similar to those in HapMap Han Chinese in Beijing, China, and no between-arm difference was observed (Supplemental Table 2 ). (31) . The adjusted R 2 was the overall variance explained in a given model. Subgroup analyses were performed according to baseline BMI, age, sex, and physical activity. Nonlinear associations between 25(OH)D and PTH at different levels were detected by locally weighted scatterplot smoothing. To test the PTH-based threshold effect of 25(OH) D, a mixed-effects model that accounted for repeatedly measured structure of our data was used to determine the associations for those participants with 25(OH)D below and above the identified breakpoint (32, 33) . Data were analyzed using SAS, version 9.3 and R software, version 3.2.3. A 2-sided P of ,0.05 was considered statistically significant.
Statistical analysis
Results
Baseline characteristics
Baseline characteristics of participants were similar between the 2 arms (Table 1) . Serum mean (6standard deviation) 25(OH)D and 25(OH)D Bio were 32.8 6 8.8 nmol/L and 2.7 6 0.8 nmol/L, respectively. A total of 411 participants completed the 20-week trial with compliance rates of 98.9% in the vitamin D 3 arm and 97.6% in the placebo arm (P = 0.92). Using the monoclonal compared with polyclonal antibody immunoassay yielded significantly lower VDBP levels (165.3 6 90.4 mg/mL vs 418.7 6 99.0 mg/mL; P , 0.001). Because Chinese have a relatively higher frequency of Gc1F, a monoclonal antibody immunoassay would have underestimated VDBP levels; the current analyses therefore used polyclonal immunoassaybased VDBP concentrations, which were similar to previous studies using the same assay (21, 34) .
Responses of 25(OH)D and 25(OH)D Bio
Compared with the placebo arm at week 20, the net changes [mean 6 standard error (SE)] in the vitamin D 3 arm were +30.6 6 1.7 nmol/L for 25(OH)D, +2.7 6 0.2 nmol/L for 25(OH)D Bio , and 25.2 6 1.2 pg/ml for PTH (P between-arm , 0.001, Table 2 ). However, by the end of 20-week supplementation, 24.6% [95% confidence interval (CI), 19.0% to 31.2%) of participants were still classified as having vitamin D deficiency according to definitions of the Institute of Medicine or the Endocrine Society in the United States (6, 35) (Table 3 ). In the placebo arm, 25(OH)D and 25(OH)D Bio increased and PTH decreased from winter to spring (P , 0.001). Meanwhile, sun exposure time was increased in both arms (P , 0.001). Mean (SE) VDBP at baseline was 418.7 6 99.0 mg/mL and remained steady during the trial (week 20, 424.3 6 108.1 mg/mL; P = 0.15). At baseline, serum calcium concentrations (albumin corrected) were positively associated with 25(OH)D Bio (r = 0.11; P , 0.001) only. Notably, only change of 25(OH)D Bio was positively associated with change of serum calcium (r = 0.22; P , 0.001) after adjusting for age, sex, and BMI (Supplemental Fig. 2 ).
Effect of genetic and nongenetic factors
At baseline, associations with 25(OH)D concentration were significant for rs4588 and rs7041 in GC (P , 0.001; Supplemental Table 3 ) and marginally significant for rs10741657 in CYP2R1 and rs1790349 in DHCR7 (P = 0.07 to 0.08). Notably, the rs4588-C allele was associated with higher VDBP and 25(OH)D concentrations (P , 0.001) with per C allele effect sizes (mean 6 SE) of 38.5 6 7.8 mg/mL and 2.2 6 0.6 nmol/L, respectively (Supplemental Table 4 ).
At week 20, vitamin D 3 significantly interacted with GC-rs7041, VDR-rs2228570, and CYP2R1-rs10741657 on 25(OH)D Bio response (P interaction = 0.04, 0.02, and 0.003, respectively; Table 4 ), but none of the selected SNPs significantly interacted with treatment on the 25(OH)D response (P interaction $ 0.07). In response to vitamin D 3 treatment, rs4588-C, rs2228570-G, and rs10741657-A alleles were associated with a greater increase in 25(OH)D (P = 0.04, 0.009, and 0.04, respectively), whereas rs7041-G, rs2228570-G, and rs10741657-A alleles were associated with greater increases in 25(OH)D Bio (P = 0.04, 0.01, and 0.003, respectively). No significant effect was detected for other SNPs (Supplemental Table 5 Table 6 ). Models including only supplement dose had an adjusted Data are means 6 standard deviation. Within-arm differences (between weeks 0, 10, and 20) were explored by using a mixed model, followed by a Fisher's least significant difference multiple comparisons test when the difference among 3 time points was significant (P , 0.05). Values with different superscript letters indicate significant differences (P , 0.05). a Only the participants who completed the trial with 3 blood samples were included in the analysis (vitamin D 3 arm, n = 207; placebo arm, n = 204). Between-arm difference at each visit time was compared by linear regression with adjustment for age, sex, BMI, and respective baseline value (except week 0). The P value for interaction (time 3 treatment) was obtained from a mixed effects model, the dose and visit time were included as fixed effects, and the participant was included as a random effect, adjusted for age, sex, and baseline BMI. In the circulation, 85% to 90% of 25(OH)D is tightly bound to VDBP, with only 10% to 15% loosely bound to albumin, and ,1% remains as free form (22) . Thus, VDBP acts as a serum carrier and reservoir of circulating 25(OH)D to maintain its levels, facilitate its transportation to various tissues, and regulate its bioavailability (22) . Based on different combinations of rs7041 and rs4588 in GC gene, 3 major isoforms of VDBP, namely Gc1F, Gc1S, and Gc2, are yielded with different binding affinities for 25(OH)D (Gc1F . Gc1S . Gc2) (40) . Interestingly, Chinese homozygotes in our trial showed larger portions of phenotypes with low/medium binding affinity (28.5% Gc2/2 and 24.3% Gc1S/1S), whereas black homozygotes tend to carry the highest binding affinity form (92.7% Gc1F/1F) (22) . Therefore, at a given 25(OH)D concentration, Chinese might have relatively higher non-VDBP-bound portions or higher 25(OH)D bioavailability than do blacks. Moreover, relatively higher frequency of Gc1F/1F in Chinese (47.2%) than whites (6.0%) may lead to underestimation of VDBP levels by using monoclonal antibody immunoassays (21) . In line with previous multiethnic studies (18, 19, 21) , we also observed a remarkably low VDBP concentration as measured by a monoclonal versus polyclonal antibody immunoassay in Chinese. Indeed, different VDBP concentrations between blacks and whites were only indicated by using the monoclonal antibody, but not by using the polyclonal antibody immunoassay or liquid chromatography-tandem mass spectrometry (19) (20) (21) . Taken together, the polyclonal antibody immunoassay is the more appropriate method to assess VDBP and also 25(OH)D Bio concentrations for the populations having a relatively higher frequency of the Gc1F/1F isoform, including blacks and Asians.
In response to vitamin D 3 treatment, we found that the polymorphisms in the genes involving the vitamin D metabolism pathway could modify the responses of 25(OH)D and/or 25(OH)D Bio specifically. For instance, GC-rs4588 CC carriers with the highest VDBP concentration showed the highest response in 25(OH)D than in other genotypes. The specific effect of rs4588-C might be largely attributed to its raising VDBP level property, as well as higher binding affinity for 25(OH)D ($1.7-fold) (40) . In fact, the VDBP-bound 25(OH)D might have a relatively long half-life by avoiding being catabolized to inactive metabolites and therefore increasing 25(OH)D concentrations (41) . Consistently, the rs4588-C allele was linked to a greater 25(OH)D response in Danish who received vitamin D 3 -fortified bread and milk or UVB treatment (42) , and also in Thais administered 400 IU/d vitamin D 3 plus calcium (41) . Unlike in the case of GC-rs4588, GC-rs7041 significantly modified the 25(OH)D Bio response, with the largest increase in rs7041-GG carriers, followed by GT and TT genotypes. (31, 44) . Moreover, compared with normal weight persons, the 25(OH)D response was much lower in overweight participants, which might be attributed to the effect of a larger volume dilution for this fat-soluble vitamin (12, 44, 45) . Other potential factors might also lead to various responses such as gastrointestinal absorption or more We used additive inheritance models (e.g., GC-rs4588 genotype groups were coded as 0, 1, and 2 in continuous form for CC, CA, and AA) in the analyses. To test potential gene-treatment interactions, a genotype-by-treatment interaction term (e.g., GC-rs4588 genotype 3 treatment/placebo group) was included in the models adjusted for age, sex, BMI, and respective baseline value. One of the major strengths of this trial is that we simultaneously studied efficacies of vitamin D 3 on elevating 25(OH)D and 25(OH)D Bio , and we also quantitatively evaluated the relative contribution of genetic and nongenetic factors to both responses. Moreover, multiple biomarkers, including PTH, calcium, albumin, and VDBP concentrations, were measured at multiple time points to evaluate responses of different portions of 25(OH)D. In this study, we measured VDBP by 2 different assays in an Asian population. Additionally, potential confounding factors were minimalized with the randomized design, relatively large sample size, and high compliance rate, as well as closely monitored dietary intake and sun exposure levels. Admittedly, our study also has some limitations: (1) All participants were Chinese adults (20 to 45 years of age), and thus the findings might not generalize to other ethnicities or different age groups. (2) 25(OH)D Bio concentrations were calculated rather than measured directly; however, a high correlation between the calculated and measured concentrations was reported previously (22) . (3) We used only the current UL in China for supplementation, and thus the effects of other doses on responses after vitamin D 3 supplementation remain to be evaluated.
In conclusion, daily supplementation with a UL dose of vitamin D in China significantly raised 25(OH)D and 25(OH)D Bio concentrations, but it was still unable to correct deficiency in 25% of participants. Genetic factors apparently exerted greater impact than did nongenetic factors on both responses. More studies are needed to elucidate appropriate vitamin D recommendation for Asians and potential clinical implications of 25(OH)D Bio . 
